| silencing HDAC7 can reset the tumor suppressor activity of STAT3, independently of the EGFR/PTEN/TP53 background of the GBM. | GBM, |
| Results show that nuclear pSTAT3 expression was associated with improved patient outcome with breast cancer while less pSTAT3 was found in tumors from patients developing metastasis. STAT3 seems to act as a tumor suppressor. | breast, |
| Results show that high ph-STAT1 and ph-STAT3 tumor cell expression were associated with increased ER and PR, reduced tumor grade and necrosis. STAT1 and STAT3 expression appeared to be an important determinant of favorable outcome in patients with invasive ductal breast cancer suggesting that both act as tumor suppressor proteins in patients with ductal breast cancer. | breast, |
| STAT3? is a tumor suppressor in acute myeloid leukemia | leukemia, |
| experiments demonstrate that Stat3 has both - tumor suppressing and tumor promoting properties | None |
| Studies indicate that STAT3 plays dual tumor suppressive and oncogenic roles in glial malignancy depending on the mutational profile of the tumor. | None |
| nuclear pSTAT3 might play a role as a tumor suppressor in high-grade salivary gland carcinomas | None |
| The tumor suppressive function of arginase-I in both infiltrating and circulating myeloid-derived suppressor cells is a downstream target of activated STAT3. | None |
| we have presented data supporting that STAT3beta is a tumor suppressor in ESCC, and STAT3beta can effectively suppress the oncogenic effects of STAT3alpha | None |
| either oncogenic or a tumour suppressor [review] | None |
| Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. | ovarian, |
| Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells. | breast, |
| Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. | leukemia, |
| STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3. | lung, |
| Results identify a cohort of STAT3 targets that may mediate its role in oncogenesis in breast and prostate cancer. | breast,prostate, |
| constitutive Stat3 signaling may be one of the key upstream regulators to induce downstream proteins which may play important roles in Stat3-mediated oncogenesis in breast cancer | breast, |
| Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. | lymphoma, |
| LKB1 suppresses tumor growth by inhibiting rearranged in transformation (RET)/papillary thyroid carcinoma-dependent activation of oncogenic STAT3 | thyroid, |
| Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC). | thyroid, |
| define a second oncogenic pathway, STAT3 activation, which operates in activated B-cell-like Diffuse large B-cell lymphoma | lymphoma, |